Viewing Company
Company Name:
VIRPAX PHARMACEUTICALS, INC.
CIK:
1708331
Phone:
None
Fiscal Year End:
None
Entity Type:
SIC:
-
Category Type:
Entity Name:
None
First Filing Date:
2021-05-17
Last Filing Date:
2025-03-03
SEC Filings
| Start | End | Frame | Filed | ACCN | Value | View |
|---|---|---|---|---|---|---|
| 2024-01-01 | 2024-03-31 | CY2024Q1 | 2024-05-13 | 0001213900-24-042284 | $ 3,500,000 | View |
| 2024-04-01 | 2024-06-30 | CY2024Q2 | 2024-08-12 | 0001213900-24-067700 | $ 7 | View |
| 2022-01-01 | 2022-12-31 | CY2022 | 2023-03-22 | 0001213900-23-022071 | $ 2,000,000 | View |
| 2023-01-01 | 2023-09-30 | CY2023Q3I | 2023-12-07 | 0001213900-23-093897 | $ 12 | View |
| 2022-01-01 | 2022-03-31 | CY2022Q1 | 2022-05-16 | 0001213900-22-027105 | $ 32,559,083 | View |
| 2021-01-01 | 2021-03-31 | CY2021Q1 | 2021-05-17 | 0001213900-21-026971 | $ 3,945,153 | View |
| 2021-04-01 | 2021-06-30 | CY2021Q2 | 2021-08-10 | 0001213900-21-041163 | $ 4,958,999 | View |
| 2021-07-01 | 2021-09-30 | CY2021Q3 | 2021-11-15 | 0001213900-21-059338 | $ 6,011,796 | View |
| 2021-01-01 | 2021-12-31 | CY2020 | 2022-03-31 | 0001213900-22-016740 | $ 6,677,271 | View |
| 2024-01-01 | 2024-09-30 | CY2024Q3I | 2024-11-14 | 0001731122-24-001812 | $ 68,200,000 | View |
| 2024-01-01 | 2024-12-31 | CY2024 | 2025-03-03 | 0001731122-25-000316 | $ 0 | View |
| 2022-01-01 | 2022-09-30 | CY2021Q3I | 2022-11-09 | 0001213900-22-070597 | $ 0 | View |
| 2023-01-01 | 2023-06-30 | CY2023Q2I | 2023-08-14 | 0001213900-23-066566 | $ 2,342 | View |
| 2023-01-01 | 2023-12-31 | CY2023 | 2024-03-26 | 0001213900-24-025781 | $ 0 | View |
| 2023-01-01 | 2023-03-31 | CY2023Q1I | 2023-05-12 | 0001213900-23-039029 | $ 25,265 | View |
| 2022-04-01 | 2022-06-30 | CY2021Q2 | 2022-08-15 | 0001213900-22-048047 | $ 11,712,753 | View |
SEC Facts By Type
| Type | Name | Description | View |
|---|---|---|---|
| us-gaap | Accrued Professional Fees, Current | Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). | View |
| us-gaap | Additional Paid in Capital | Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. | View |
| us-gaap | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. | View |
| us-gaap | Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense | Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans). | View |
| us-gaap | Deferred Compensation Liability, Current | Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date. | View |
| us-gaap | Deferred Costs, Noncurrent | Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent. | View |
| us-gaap | Earnings Per Share, Basic and Diluted | The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | View |
| us-gaap | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | Amount of cost to be recognized for option under share-based payment arrangement. | View |
| us-gaap | Equity Method Investment, Ownership Percentage | The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. | View |
| us-gaap | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. | View |
| us-gaap | Notes Payable, Noncurrent | Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. | View |
| us-gaap | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. | View |
| us-gaap | Notes Payable | Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. | View |
| us-gaap | Notes Payable, Current | Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. | View |
| us-gaap | Notes Payable, Related Parties | The amount for notes payable (written promise to pay), due to related parties. | View |
| us-gaap | Proceeds from Related Party Debt | The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates. | View |
| us-gaap | Research and Development Expense | The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Gross number of share options (or share units) granted during the period. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | Number of options outstanding, including both vested and non-vested options. | View |
| us-gaap | Weighted Average Number Diluted Shares Outstanding Adjustment | The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. | View |
| us-gaap | Weighted Average Number of Shares Outstanding, Basic and Diluted | Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). | View |
| us-gaap | Deferred Tax Assets, in Process Research and Development | Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination. | View |
| us-gaap | Deferred Tax Assets, Net of Valuation Allowance | Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. | View |
| us-gaap | Deferred Tax Assets, Operating Loss Carryforwards | Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. | View |
| us-gaap | Deferred Tax Assets, Operating Loss Carryforwards, State and Local | Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards. | View |
| us-gaap | Deferred Tax Assets, Other | Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other. | View |
| us-gaap | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. | View |
| us-gaap | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity. | View |
| us-gaap | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | View |
| us-gaap | Prepaid Expense and Other Assets, Noncurrent | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer. | View |
| us-gaap | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit | The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. | View |
| us-gaap | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | View |
| us-gaap | Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. | View |
| us-gaap | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent | Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement. | View |
| us-gaap | Adjustments to Additional Paid in Capital, Fair Value | Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned. | View |
| us-gaap | Preferred Stock, Shares Issued | Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. | View |
| us-gaap | Deferred Tax Assets, Net | Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting. | View |
| dei | Entity Common Stock, Shares Outstanding | Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. | View |
| dei | Entity Public Float | The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. | View |
| us-gaap | Accounts Payable and Accrued Liabilities, Current | Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. | View |
| us-gaap | Accounts Payable, Fair Value Disclosure | Fair value portion of liabilities incurred for goods and services received that are used in an entity's business and related party payables. | View |
| us-gaap | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). | View |
| us-gaap | Proceeds from Notes Payable | The cash inflow from a borrowing supported by a written promise to pay an obligation. | View |
| us-gaap | Adjustments to Additional Paid in Capital, Stock Split | Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately. | View |
| us-gaap | Share-based Payment Arrangement, Expense | Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. | View |
| us-gaap | Assets | Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | View |
| us-gaap | Assets, Current | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | View |
| us-gaap | Cash | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. | View |
| us-gaap | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. | View |
| us-gaap | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. | View |
| us-gaap | Common Stock, Convertible, Conversion Price, Increase | Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision. | View |
| us-gaap | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | View |
| us-gaap | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | View |
| us-gaap | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | View |
| us-gaap | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | View |
| us-gaap | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. | View |
| us-gaap | Debt Instrument, Face Amount | Face (par) amount of debt instrument at time of issuance. | View |
| us-gaap | Debt Instrument, Increase, Accrued Interest | Increase for accrued, but unpaid interest on the debt instrument for the period. | View |
| us-gaap | Debt Instrument, Increase (Decrease), Other, Net | Amount of increase (decrease) in debt instruments, classified as other. | View |
| us-gaap | Debt, Weighted Average Interest Rate | Weighted average interest rate of debt outstanding. | View |
| us-gaap | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | View |
| us-gaap | Increase (Decrease) in Accounts Payable and Accrued Liabilities | The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. | View |
| us-gaap | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. | View |
| us-gaap | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants | Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method. | View |
| us-gaap | Interest Expense | Amount of the cost of borrowed funds accounted for as interest expense. | View |
| us-gaap | Interest Expense, Debt | Amount of the cost of borrowed funds accounted for as interest expense for debt. | View |
| us-gaap | Interest Paid, Excluding Capitalized Interest, Operating Activities | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. | View |
| us-gaap | Liabilities | Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. | View |
| us-gaap | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. | View |
| us-gaap | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. | View |
| us-gaap | Liabilities, Noncurrent | Amount of obligation due after one year or beyond the normal operating cycle, if longer. | View |
| us-gaap | Long-term Debt | Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations. | View |
| us-gaap | Long-Term Debt, Maturity, Year One | Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). | View |
| us-gaap | Long-Term Debt, Maturity, Year Three | Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). | View |
| us-gaap | Long-Term Debt, Maturity, Year Two | Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). | View |
| us-gaap | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | View |
| us-gaap | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | View |
| us-gaap | Net Income (Loss) Attributable to Parent, Diluted | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions. | View |
| us-gaap | Notes and Loans Payable, Current | Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer. | View |
| us-gaap | Notes Payable, Related Parties, Noncurrent | The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle). | View |
| us-gaap | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. | View |
| us-gaap | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. | View |
| us-gaap | Other Accounts Payable and Accrued Liabilities | Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer. | View |
| us-gaap | Other General and Administrative Expense | Amount of general and administrative expense classified as other. | View |
| us-gaap | Other Notes Payable, Noncurrent | Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer. | View |
| us-gaap | Other Noncash Expense | Amount of expense or loss included in net income that result in no cash flow, classified as other. | View |
| us-gaap | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. | View |
| us-gaap | Other Prepaid Expense, Current | Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. | View |
| us-gaap | Other Research and Development Expense | Amount of other research and development expense. | View |
| us-gaap | Payments of Financing Costs | The cash outflow for loan and debt issuance costs. | View |
| us-gaap | Payments of Stock Issuance Costs | The cash outflow for cost incurred directly with the issuance of an equity security. | View |
| us-gaap | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | View |
| us-gaap | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | View |
| us-gaap | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. | View |
| us-gaap | Prepaid Insurance | Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. | View |
| us-gaap | Proceeds from Debt, Net of Issuance Costs | The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. | View |
| us-gaap | Proceeds from Issuance Initial Public Offering | The cash inflow associated with the amount received from entity's first offering of stock to the public. | View |
| us-gaap | Proceeds from Issuance of Common Stock | The cash inflow from the additional capital contribution to the entity. | View |
| us-gaap | Proceeds from Issuance of Debt | The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. | View |
| us-gaap | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. | View |
| us-gaap | Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party | Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party. | View |
| us-gaap | Repayments of Debt | The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations. | View |
| us-gaap | Repayments of Notes Payable | The cash outflow for a borrowing supported by a written promise to pay an obligation. | View |
| us-gaap | Repayments of Related Party Debt | The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates. | View |
| us-gaap | Restricted Stock, Value, Shares Issued Net of Tax Withholdings | Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. | View |
| us-gaap | Retained Earnings (Accumulated Deficit) | The cumulative amount of the reporting entity's undistributed earnings or deficit. | View |
| us-gaap | Sale Leaseback Transaction, Gross Proceeds, Investing Activities | Amount of cash inflow before closing and debt issuance costs received by a seller-lessee in a sale-leaseback recognized in investing activities. | View |
| us-gaap | Sale of Stock, Consideration Received on Transaction | Cash received on stock transaction after deduction of issuance costs. | View |
| us-gaap | Sale of Stock, Price Per Share | Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. | View |
| us-gaap | Share-based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | The risk-free interest rate assumption that is used in valuing an option on its own shares. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate | Rate of weighted-average expected volatility for award under share-based payment arrangement. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. | View |
| us-gaap | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | Weighted average price at which option holders acquired shares when converting their stock options into shares. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. | View |
| us-gaap | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. | View |
| us-gaap | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. | View |
| us-gaap | Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | Purchase price of common stock expressed as a percentage of its fair value. | View |
| us-gaap | Shares, Issued | Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. | View |
| us-gaap | Shares Issued, Price Per Share | Per share or per unit amount of equity securities issued. | View |
| us-gaap | Stockholders' Equity Attributable to Parent | Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. | View |
| us-gaap | Stock Issued During Period, Shares, Employee Stock Purchase Plans | Number of shares issued during the period as a result of an employee stock purchase plan. | View |
| us-gaap | Stock Issued During Period, Shares, New Issues | Number of new stock issued during the period. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | Number of share options (or share units) exercised during the current period. | View |
| us-gaap | Stock Issued During Period, Value, Issued for Services | Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. | View |
| us-gaap | Stock Issued During Period, Value, New Issues | Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. | View |
| us-gaap | Stock Issued During Period, Value, Other | Value of shares of stock issued attributable to transactions classified as other. | View |
| us-gaap | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture | Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). | View |
| us-gaap | Unearned Premiums | Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date. | View |
| us-gaap | Warrant, Exercise Price, Increase | Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision. | View |
| us-gaap | Deferred Tax Assets, Gross | Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. | View |
| us-gaap | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities. | View |
| us-gaap | Deferred Tax Assets, Valuation Allowance | Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. | View |
| us-gaap | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | View |
| us-gaap | Effective Income Tax Rate Reconciliation, Percent | Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. | View |
| us-gaap | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | Percentage of domestic federal statutory tax rate applicable to pretax income (loss). | View |
| us-gaap | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets. | View |
| us-gaap | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments. | View |
| us-gaap | Increase (Decrease) in Deferred Charges | The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation. | View |
| us-gaap | Investment Company, Distributable Earnings | Amount of accumulated undistributed tax basis earnings (deficit). | View |
| us-gaap | Operating Loss Carryforwards | Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. | View |
| us-gaap | Other Nonoperating Income | Amount of income related to nonoperating activities, classified as other. | View |
| us-gaap | Research and Development in Process | The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. | View |
| us-gaap | Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost | The excess of the fair value of the modified award over the fair value of the award immediately before the modification. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares | Number of non-vested options forfeited. | View |
| us-gaap | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | View |
| us-gaap | Deferred Compensation Arrangement with Individual, Exercise Price | The per share price that the individual must pay to acquire shares under the deferred compensation arrangement. | View |
| us-gaap | Other Income | Amount of revenue and income classified as other. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) | The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. | View |
| us-gaap | Payments for Repurchase of Initial Public Offering | The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public. | View |
| us-gaap | Class of Warrant or Right, Exercise Price of Warrants or Rights | Exercise price per share or per unit of warrants or rights outstanding. | View |
| us-gaap | Class of Warrant or Right, Outstanding | Number of warrants or rights outstanding. | View |
| us-gaap | Dividends, Cash | Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price | Weighted average grant-date fair value of non-vested options outstanding. | View |
| us-gaap | Accounts Payable and Accrued Liabilities | Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations. | View |
| us-gaap | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement. | View |
| us-gaap | Deferred Tax Assets, Other Tax Carryforwards | Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other. | View |
| us-gaap | Gains (Losses) on Restructuring of Debt | For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete. | View |
| us-gaap | Legal Fees | The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. | View |
| us-gaap | Other Expenses | Amount of expense classified as other. | View |
| us-gaap | Premiums Earned, Net, Other Insurance | Amount, after premiums ceded to other entities and premiums assumed by the entity, of other types of premiums earned. | View |
| us-gaap | Research and Development Expense (Excluding Acquired in Process Cost) | The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. | View |
| us-gaap | Stock Issued During Period, Shares, Restricted Stock Award, Forfeited | Number of shares related to Restricted Stock Award forfeited during the period. | View |
| us-gaap | Stock Issued During Period, Shares, Restricted Stock Award, Gross | Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. | View |
| us-gaap | Deferred Tax Expense from Stock Options Exercised | Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise. | View |
| us-gaap | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs | Amount of deferred tax liability attributable to taxable temporary differences from research and development costs. | View |
| us-gaap | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit). | View |
| us-gaap | Increase (Decrease) in Other Current Liabilities | Amount of increase (decrease) in current liabilities classified as other. | View |
| us-gaap | Estimated Litigation Liability, Current | Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position. | View |
| us-gaap | Cash, FDIC Insured Amount | The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation. | View |
| us-gaap | Employee Benefits and Share-based Compensation | Amount of expense for employee benefit and equity-based compensation. | View |
| us-gaap | Professional Fees | A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. | View |
| us-gaap | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount | Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense. | View |
| us-gaap | Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred | The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government. | View |
| us-gaap | Research and Development Expense, Software (Excluding Acquired in Process Cost) | Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | Number of options vested. | View |
| us-gaap | Accrued Employee Benefits, Current | Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). | View |
| us-gaap | Accrued Insurance, Current | Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). | View |
| us-gaap | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement. | View |
| us-gaap | Loss Contingency, Accrual, Current | Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer. | View |
| us-gaap | Litigation Settlement Interest | Interest expense (income) directly attributable to an award in settlement of litigation. | View |
| us-gaap | Loss Contingency Accrual, Product Liability, Gross | Undiscounted amount of the accrual for damages arising from third-party use of the entity's product or process. | View |
| us-gaap | Loss Contingency, Damages Awarded, Value | Amount of damages awarded to the plaintiff in the legal matter. | View |
| us-gaap | Loss Contingency, Damages Paid, Value | Amount of damages paid to the plaintiff in the legal matter. | View |
| us-gaap | Other Accrued Liabilities, Current | Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. | View |
| us-gaap | Other Selling, General and Administrative Expense | Amount of selling, general and administrative expense classified as other. | View |
| us-gaap | Payments for Other Fees | Amount of cash outflow for fees classified as other. | View |
| us-gaap | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. | View |
| us-gaap | Stock Issued | The fair value of stock issued in noncash financing activities. | View |
| us-gaap | Stock Option, Exercise Price, Decrease | Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement. | View |
| us-gaap | Accounts Payable, Trade | Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. | View |
| us-gaap | Accrued Payroll Taxes, Current | Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). | View |
| us-gaap | Current Federal, State and Local, Tax Expense (Benefit) | Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations. | View |
| us-gaap | Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent | Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense. | View |
| us-gaap | Income Tax Credits and Adjustments | A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions. | View |
| us-gaap | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets. | View |
| us-gaap | Insurance Recoveries | The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses. | View |
| us-gaap | Line of Credit Facility, Annual Principal Payment | Amount of the total principal payments made during the annual reporting period. | View |
| us-gaap | Loss Contingency, Damages Sought, Value | The value (monetary amount) of the award the plaintiff seeks in the legal matter. | View |
| us-gaap | Nonoperating Income (Expense) | The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). | View |
| us-gaap | Preferred Stock, Dividend Rate, Percentage | The percentage rate used to calculate dividend payments on preferred stock. | View |
| us-gaap | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross | The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. | View |
| us-gaap | Common Stock, Capital Shares Reserved for Future Issuance | Aggregate number of common shares reserved for future issuance. | View |
| us-gaap | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | Amount of cost not yet recognized for nonvested award under share-based payment arrangement. | View |
| us-gaap | Indefinite-Lived License Agreements | Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit. | View |
| us-gaap | Litigation Settlement, Amount Awarded to Other Party | Amount awarded to other party in judgment or settlement of litigation. | View |
| us-gaap | 3261697 | None | View |
| us-gaap | Obligation with Joint and Several Liability Arrangement, Amount Outstanding | Amount outstanding, before the effects of recovery, of obligation under the joint and several liability arrangement. | View |
| us-gaap | Shares Issued, Shares, Share-based Payment Arrangement, Forfeited | Number of shares (or other type of equity) forfeited during the period. | View |
| us-gaap | Stock Issued During Period, Value, Stock Options Exercised | Value of stock issued as a result of the exercise of stock options. | View |
| us-gaap | Litigation Settlement, Expense | Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. | View |
| us-gaap | Net Income (Loss) Available to Common Stockholders, Basic | Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. | View |
| us-gaap | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | View |
| us-gaap | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. | View |
| us-gaap | Retained Earnings, Appropriated | A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies. | View |
| srt | 3261707 | None | View |
Chart of Accounts => Accounts
| Name | View |
|---|---|
| Other Prepaid Expense, Current | View |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | View |
| Common Stock, Convertible, Conversion Price, Increase | View |
| Common Stock, Par or Stated Value Per Share | View |
| Deferred Compensation Liability, Current | View |
| Deferred Costs, Noncurrent | View |
| Earnings Per Share, Basic and Diluted | View |
| Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | View |
| Equity Method Investment, Ownership Percentage | View |
| General and Administrative Expense | View |
| Other Research and Development Expense | View |
| Preferred Stock, Shares Authorized | View |
| Prepaid Expense and Other Assets, Current | View |
| Prepaid Insurance | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | View |
| Deferred Tax Assets, Operating Loss Carryforwards, State and Local | View |
| Deferred Tax Assets, Other | View |
| Prepaid Expense and Other Assets, Noncurrent | View |
| Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price | View |
| Weighted Average Number of Shares Outstanding, Diluted | View |
| Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | View |
| Deferred Tax Assets, Net | View |
| Accounts Payable and Accrued Liabilities, Current | View |
| Accounts Payable, Fair Value Disclosure | View |
| Accrued Liabilities, Current | View |
| Accrued Professional Fees, Current | View |
| Additional Paid in Capital | View |
| Adjustments to Additional Paid in Capital, Stock Split | View |
| Share-based Payment Arrangement, Expense | View |
| Assets | View |
| Assets, Current | View |
| Cash | View |
| Cash and Cash Equivalents, at Carrying Value | View |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | View |
| Common Stock, Shares Authorized | View |
| Common Stock, Shares, Issued | View |
| Common Stock, Shares, Outstanding | View |
| Common Stock, Value, Issued | View |
| Debt Instrument, Face Amount | View |
| Debt Instrument, Increase, Accrued Interest | View |
| Debt Instrument, Increase (Decrease), Other, Net | View |
| Debt, Weighted Average Interest Rate | View |
| Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense | View |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | View |
| Increase (Decrease) in Accounts Payable and Accrued Liabilities | View |
| Increase (Decrease) in Prepaid Expense and Other Assets | View |
| Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants | View |
| Interest Expense | View |
| Interest Expense, Debt | View |
| Interest Paid, Excluding Capitalized Interest, Operating Activities | View |
| Liabilities | View |
| Liabilities and Equity | View |
| Liabilities, Current | View |
| Liabilities, Noncurrent | View |
| Long-term Debt | View |
| Long-Term Debt, Maturity, Year One | View |
| Long-Term Debt, Maturity, Year Three | View |
| Long-Term Debt, Maturity, Year Two | View |
| Notes Payable, Noncurrent | View |
| Net Cash Provided by (Used in) Financing Activities | View |
| Net Cash Provided by (Used in) Operating Activities | View |
| Net Income (Loss) Attributable to Parent | View |
| Net Income (Loss) Attributable to Parent, Diluted | View |
| Notes and Loans Payable, Current | View |
| Notes Payable | View |
| Notes Payable, Current | View |
| Notes Payable, Related Parties | View |
| Notes Payable, Related Parties, Noncurrent | View |
| Operating Expenses | View |
| Operating Income (Loss) | View |
| Other Accounts Payable and Accrued Liabilities | View |
| Other General and Administrative Expense | View |
| Other Notes Payable, Noncurrent | View |
| Other Noncash Expense | View |
| Other Nonoperating Income (Expense) | View |
| Payments of Financing Costs | View |
| Payments of Stock Issuance Costs | View |
| Preferred Stock, Par or Stated Value Per Share | View |
| Proceeds from Debt, Net of Issuance Costs | View |
| Proceeds from Issuance Initial Public Offering | View |
| Proceeds from Issuance of Common Stock | View |
| Proceeds from Issuance of Debt | View |
| Proceeds from Notes Payable | View |
| Proceeds from Related Party Debt | View |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | View |
| Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party | View |
| Repayments of Debt | View |
| Repayments of Notes Payable | View |
| Repayments of Related Party Debt | View |
| Research and Development Expense | View |
| Restricted Stock, Value, Shares Issued Net of Tax Withholdings | View |
| Retained Earnings (Accumulated Deficit) | View |
| Sale Leaseback Transaction, Gross Proceeds, Investing Activities | View |
| Sale of Stock, Consideration Received on Transaction | View |
| Sale of Stock, Price Per Share | View |
| Share-based Payment Arrangement, Noncash Expense | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | View |
| Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | View |
| Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | View |
| Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | View |
| Shares, Issued | View |
| Shares Issued, Price Per Share | View |
| Stockholders' Equity Attributable to Parent | View |
| Stock Issued During Period, Shares, Employee Stock Purchase Plans | View |
| Stock Issued During Period, Shares, New Issues | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | View |
| Stock Issued During Period, Value, Issued for Services | View |
| Stock Issued During Period, Value, New Issues | View |
| Stock Issued During Period, Value, Other | View |
| Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture | View |
| Unearned Premiums | View |
| Warrant, Exercise Price, Increase | View |
| Weighted Average Number Diluted Shares Outstanding Adjustment | View |
| Weighted Average Number of Shares Outstanding, Basic and Diluted | View |
| Deferred Tax Assets, Gross | View |
| Deferred Tax Assets, in Process Research and Development | View |
| Deferred Tax Assets, Net of Valuation Allowance | View |
| Deferred Tax Assets, Operating Loss Carryforwards | View |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | View |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | View |
| Deferred Tax Assets, Valuation Allowance | View |
| Earnings Per Share, Basic | View |
| Effective Income Tax Rate Reconciliation, Percent | View |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | View |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | View |
| Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | View |
| Increase (Decrease) in Deferred Charges | View |
| Investment Company, Distributable Earnings | View |
| Operating Loss Carryforwards | View |
| Other Nonoperating Income | View |
| Research and Development in Process | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | View |
| Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares | View |
| Weighted Average Number of Shares Outstanding, Basic | View |
| Deferred Compensation Arrangement with Individual, Exercise Price | View |
| Other Income | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | View |
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | View |
| Class of Warrant or Right, Exercise Price of Warrants or Rights | View |
| Class of Warrant or Right, Outstanding | View |
| Dividends, Cash | View |
| Earnings Per Share, Diluted | View |
| Accounts Payable and Accrued Liabilities | View |
| APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition | View |
| Deferred Tax Assets, Other Tax Carryforwards | View |
| Gains (Losses) on Restructuring of Debt | View |
| Legal Fees | View |
| Other Expenses | View |
| Premiums Earned, Net, Other Insurance | View |
| Research and Development Expense (Excluding Acquired in Process Cost) | View |
| Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | View |
| Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | View |
| Stock Issued During Period, Shares, Restricted Stock Award, Forfeited | View |
| Stock Issued During Period, Shares, Restricted Stock Award, Gross | View |
| Deferred Tax Expense from Stock Options Exercised | View |
| Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs | View |
| Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | View |
| Increase (Decrease) in Other Current Liabilities | View |
| Estimated Litigation Liability, Current | View |
| Cash, FDIC Insured Amount | View |
| Employee Benefits and Share-based Compensation | View |
| Professional Fees | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | View |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount | View |
| Research and Development Expense, Software (Excluding Acquired in Process Cost) | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | View |
| Accrued Employee Benefits, Current | View |
| Accrued Insurance, Current | View |
| APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition | View |
| Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent | View |
| Litigation Settlement Interest | View |
| Loss Contingency Accrual, Product Liability, Gross | View |
| Loss Contingency, Damages Awarded, Value | View |
| Loss Contingency, Damages Paid, Value | View |
| Other Accrued Liabilities, Current | View |
| Other Selling, General and Administrative Expense | View |
| Payments for Other Fees | View |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | View |
| Stock Issued | View |
| Stock Option, Exercise Price, Decrease | View |
| Accounts Payable, Trade | View |
| Accrued Payroll Taxes, Current | View |
| Current Federal, State and Local, Tax Expense (Benefit) | View |
| Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent | View |
| Income Tax Credits and Adjustments | View |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | View |
| Insurance Recoveries | View |
| Line of Credit Facility, Annual Principal Payment | View |
| Loss Contingency, Damages Sought, Value | View |
| Nonoperating Income (Expense) | View |
| Preferred Stock, Dividend Rate, Percentage | View |
| Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross | View |
| Common Stock, Capital Shares Reserved for Future Issuance | View |
| Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | View |
| Indefinite-Lived License Agreements | View |
| Litigation Settlement, Amount Awarded to Other Party | View |
| Loss Contingency, Accrual, Current | View |
| Payments for Repurchase of Initial Public Offering | View |
| Adjustments to Additional Paid in Capital, Fair Value | View |
| 3233222 | View |
| Obligation with Joint and Several Liability Arrangement, Amount Outstanding | View |
| Shares Issued, Shares, Share-based Payment Arrangement, Forfeited | View |
| Stock Issued During Period, Value, Stock Options Exercised | View |
| Litigation Settlement, Expense | View |
| Net Income (Loss) Available to Common Stockholders, Basic | View |
| Preferred Stock, Shares Issued | View |
| Preferred Stock, Shares Outstanding | View |
| Preferred Stock, Value, Issued | View |
| Retained Earnings, Appropriated | View |